487 related articles for article (PubMed ID: 25489853)
41. Inhibition of human DNA topoisomerase IIα by two novel ellipticine derivatives.
Vann KR; Ergün Y; Zencir S; Oncuoglu S; Osheroff N; Topcu Z
Bioorg Med Chem Lett; 2016 Apr; 26(7):1809-12. PubMed ID: 26906637
[TBL] [Abstract][Full Text] [Related]
42. Recent advances in the development of catalytic inhibitors of human DNA topoisomerase IIα as novel anticancer agents.
Pogorelčnik B; Perdih A; Solmajer T
Curr Med Chem; 2013; 20(5):694-709. PubMed ID: 23210851
[TBL] [Abstract][Full Text] [Related]
43. Structural determinants of the catalytic inhibition of human topoisomerase IIα by salicylate analogs and salicylate-based drugs.
Bau JT; Kurz EU
Biochem Pharmacol; 2014 Jun; 89(4):464-76. PubMed ID: 24695359
[TBL] [Abstract][Full Text] [Related]
44. Effects of Olive Metabolites on DNA Cleavage Mediated by Human Type II Topoisomerases.
Vann KR; Sedgeman CA; Gopas J; Golan-Goldhirsh A; Osheroff N
Biochemistry; 2015 Jul; 54(29):4531-41. PubMed ID: 26132160
[TBL] [Abstract][Full Text] [Related]
45. The impact of the C-terminal domain on the interaction of human DNA topoisomerase II α and β with DNA.
Gilroy KL; Austin CA
PLoS One; 2011 Feb; 6(2):e14693. PubMed ID: 21358820
[TBL] [Abstract][Full Text] [Related]
46. Cyclometalated platinum(II) complexes as topoisomerase IIα poisons.
Liu J; Leung CH; Chow AL; Sun RW; Yan SC; Che CM
Chem Commun (Camb); 2011 Jan; 47(2):719-21. PubMed ID: 21072335
[TBL] [Abstract][Full Text] [Related]
47. Topoisomerases as anticancer targets.
Delgado JL; Hsieh CM; Chan NL; Hiasa H
Biochem J; 2018 Jan; 475(2):373-398. PubMed ID: 29363591
[TBL] [Abstract][Full Text] [Related]
48. Design, synthesis, topoisomerase I & II inhibitory activity, antiproliferative activity, and structure-activity relationship study of pyrazoline derivatives: An ATP-competitive human topoisomerase IIα catalytic inhibitor.
Ahmad P; Woo H; Jun KY; Kadi AA; Abdel-Aziz HA; Kwon Y; Rahman AF
Bioorg Med Chem; 2016 Apr; 24(8):1898-908. PubMed ID: 26988802
[TBL] [Abstract][Full Text] [Related]
49. Topoisomerase IIα, rather than IIβ, is a promising target in development of anti-cancer drugs.
Chen W; Qiu J; Shen YM
Drug Discov Ther; 2012 Oct; 6(5):230-7. PubMed ID: 23229142
[TBL] [Abstract][Full Text] [Related]
50. C-terminal regions of topoisomerase IIalpha and IIbeta determine isoform-specific functioning of the enzymes in vivo.
Linka RM; Porter AC; Volkov A; Mielke C; Boege F; Christensen MO
Nucleic Acids Res; 2007; 35(11):3810-22. PubMed ID: 17526531
[TBL] [Abstract][Full Text] [Related]
51. Contributions of the D-Ring to the activity of etoposide against human topoisomerase IIα: potential interactions with DNA in the ternary enzyme--drug--DNA complex.
Pitts SL; Jablonksy MJ; Duca M; Dauzonne D; Monneret C; Arimondo PB; Anklin C; Graves DE; Osheroff N
Biochemistry; 2011 Jun; 50(22):5058-66. PubMed ID: 21548574
[TBL] [Abstract][Full Text] [Related]
52. Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform.
Hasinoff BB; Wu X; Patel D; Kanagasabai R; Karmahapatra S; Yalowich JC
J Pharmacol Exp Ther; 2016 Feb; 356(2):397-409. PubMed ID: 26660439
[TBL] [Abstract][Full Text] [Related]
53. Polyamine-containing etoposide derivatives as poisons of human type II topoisomerases: Differential effects on topoisomerase IIα and IIβ.
Oviatt AA; Kuriappan JA; Minniti E; Vann KR; Onuorah P; Minarini A; De Vivo M; Osheroff N
Bioorg Med Chem Lett; 2018 Sep; 28(17):2961-2968. PubMed ID: 30006062
[TBL] [Abstract][Full Text] [Related]
54. Design, synthesis, cytotoxicity, HuTopoIIα inhibitory activity and molecular docking studies of pyrazole derivatives as potential anticancer agents.
Alam R; Wahi D; Singh R; Sinha D; Tandon V; Grover A; Rahisuddin
Bioorg Chem; 2016 Dec; 69():77-90. PubMed ID: 27744115
[TBL] [Abstract][Full Text] [Related]
55. Natural products as topoisomerase II poisons: effects of thymoquinone on DNA cleavage mediated by human topoisomerase IIα.
Ashley RE; Osheroff N
Chem Res Toxicol; 2014 May; 27(5):787-93. PubMed ID: 24650156
[TBL] [Abstract][Full Text] [Related]
56. Two-Mechanism Model for the Interaction of Etoposide Quinone with Topoisomerase IIα.
Gibson EG; King MM; Mercer SL; Deweese JE
Chem Res Toxicol; 2016 Sep; 29(9):1541-8. PubMed ID: 27533850
[TBL] [Abstract][Full Text] [Related]
57. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.
Marchion DC; Bicaku E; Turner JG; Daud AI; Sullivan DM; Munster PN
Clin Cancer Res; 2005 Dec; 11(23):8467-75. PubMed ID: 16322310
[TBL] [Abstract][Full Text] [Related]
58. [Poisons of DNA topoisomerases I and II].
Charcosset JY; Soues S; Laval F
Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034
[TBL] [Abstract][Full Text] [Related]
59. Interactions between the etoposide derivative F14512 and human type II topoisomerases: implications for the C4 spermine moiety in promoting enzyme-mediated DNA cleavage.
Gentry AC; Pitts SL; Jablonsky MJ; Bailly C; Graves DE; Osheroff N
Biochemistry; 2011 Apr; 50(15):3240-9. PubMed ID: 21413765
[TBL] [Abstract][Full Text] [Related]
60. Hydroxylated 2,4-diphenyl indenopyridine derivatives as a selective non-intercalative topoisomerase IIα catalytic inhibitor.
Kadayat TM; Park C; Jun KY; Thapa Magar TB; Bist G; Yoo HY; Kwon Y; Lee ES
Eur J Med Chem; 2015 Jan; 90():302-14. PubMed ID: 25437617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
